184 related articles for article (PubMed ID: 10699927)
81. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
Wang YH; Takanashi M; Tsuji K; Tanaka N; Shiseki M; Mori N; Motoji T
Leuk Res; 2009 Jul; 33(7):902-7. PubMed ID: 19185918
[TBL] [Abstract][Full Text] [Related]
82. Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide.
Hochhauser D; Kotecha M; O'hare C; Morris PJ; Hartley JM; Taherbhai Z; Harris D; Forni C; Mantovani R; Lee M; Hartley JA
Mol Cancer Ther; 2007 Jan; 6(1):346-54. PubMed ID: 17237293
[TBL] [Abstract][Full Text] [Related]
83. Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting.
Padget K; Pearson AD; Austin CA
Leukemia; 2000 Nov; 14(11):1997-2005. PubMed ID: 11069037
[TBL] [Abstract][Full Text] [Related]
84. Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression.
Salmena L; Lam V; McPherson JP; Goldenberg GJ
Biochem Pharmacol; 2001 Apr; 61(7):795-802. PubMed ID: 11274964
[TBL] [Abstract][Full Text] [Related]
85. Co-localization of chicken DNA topoisomerase IIalpha, but not beta, with sites of DNA replication and possible involvement of a C-terminal region of alpha through its binding to PCNA.
Niimi A; Suka N; Harata M; Kikuchi A; Mizuno S
Chromosoma; 2001 May; 110(2):102-14. PubMed ID: 11453553
[TBL] [Abstract][Full Text] [Related]
86. Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation.
Adachi N; Nomoto M; Kohno K; Koyama H
Gene; 2000 Mar; 245(1):49-57. PubMed ID: 10713444
[TBL] [Abstract][Full Text] [Related]
87. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
Withoff S; Smit EF; Meersma GJ; van den Berg A; Timmer-Bosscha H; Kok K; Postmus PE; Mulder NH; de Vries EG; Buys CH
Lab Invest; 1994 Jul; 71(1):61-6. PubMed ID: 8041119
[TBL] [Abstract][Full Text] [Related]
88. Decreased expression of topoisomerase IIbeta in poly(ADP-ribose) polymerase-deficient cells.
Canitrot Y; de Murcia G; Salles B
Nucleic Acids Res; 1998 Nov; 26(22):5134-8. PubMed ID: 9801310
[TBL] [Abstract][Full Text] [Related]
89. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
[TBL] [Abstract][Full Text] [Related]
90. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
91. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
92. Smurf2-Mediated Stabilization of DNA Topoisomerase IIα Controls Genomic Integrity.
Emanuelli A; Borroni AP; Apel-Sarid L; Shah PA; Ayyathan DM; Koganti P; Levy-Cohen G; Blank M
Cancer Res; 2017 Aug; 77(16):4217-4227. PubMed ID: 28611047
[TBL] [Abstract][Full Text] [Related]
93. Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.
Yoon JH; Kim JK; Rha GB; Oh M; Park SH; Seong RH; Hong SH; Park SD
Biochem J; 1999 Dec; 344 Pt 2(Pt 2):367-74. PubMed ID: 10567217
[TBL] [Abstract][Full Text] [Related]
94. Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.
Sng JH; Heaton VJ; Bell M; Maini P; Austin CA; Fisher LM
Biochim Biophys Acta; 1999 Mar; 1444(3):395-406. PubMed ID: 10095062
[TBL] [Abstract][Full Text] [Related]
95. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F
Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046
[TBL] [Abstract][Full Text] [Related]
96. Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.
Hernandez VA; Carvajal-Moreno J; Wang X; Pietrzak M; Yalowich JC; Elton TS
PLoS One; 2022; 17(5):e0265794. PubMed ID: 35617303
[TBL] [Abstract][Full Text] [Related]
97. Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance.
Heenan M; O'Driscoll L; Cleary I; Connolly L; Clynes M
Int J Cancer; 1997 May; 71(5):907-15. PubMed ID: 9180164
[TBL] [Abstract][Full Text] [Related]
98. QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells.
Chen MC; Pan SL; Shi Q; Xiao Z; Lee KH; Li TK; Teng CM
Cancer Sci; 2012 Jan; 103(1):80-7. PubMed ID: 21920000
[TBL] [Abstract][Full Text] [Related]
99. Down-regulation of human topoisomerase IIalpha correlates with altered expression of transcriptional regulators NF-YA and Sp1.
Allen KA; Williams AO; Isaacs RJ; Stowell KM
Anticancer Drugs; 2004 Apr; 15(4):357-62. PubMed ID: 15057140
[TBL] [Abstract][Full Text] [Related]
100. Regulation of catalytic activity and nucleolar localization of rat DNA topoisomerase IIα through its C-terminal domain.
Yasuda K; Kato Y; Ikeda S; Kawano S
Genes Genet Syst; 2021 Mar; 95(6):291-302. PubMed ID: 33551432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
